A detailed history of Eagle Asset Management Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Eagle Asset Management Inc holds 624,759 shares of ITCI stock, worth $80.3 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
624,759
Previous 271,036 130.51%
Holding current value
$80.3 Million
Previous $18.6 Million 146.09%
% of portfolio
0.27%
Previous 0.1%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$67.99 - $80.84 $24 Million - $28.6 Million
353,723 Added 130.51%
624,759 $45.7 Million
Q2 2024

Aug 12, 2024

SELL
$64.76 - $79.84 $5.27 Million - $6.49 Million
-81,306 Reduced 23.08%
271,036 $18.6 Million
Q1 2024

May 09, 2024

SELL
$64.37 - $75.65 $5.37 Million - $6.31 Million
-83,376 Reduced 19.14%
352,342 $24.4 Million
Q4 2023

Feb 12, 2024

BUY
$46.37 - $73.65 $1.05 Million - $1.67 Million
22,628 Added 5.48%
435,718 $31.2 Million
Q3 2023

Nov 13, 2023

BUY
$52.09 - $64.1 $744,366 - $915,988
14,290 Added 3.58%
413,090 $21.5 Million
Q2 2023

Aug 09, 2023

BUY
$54.67 - $66.44 $9.41 Million - $11.4 Million
172,147 Added 75.95%
398,800 $25.3 Million
Q1 2023

May 08, 2023

SELL
$43.8 - $56.99 $1.76 Million - $2.29 Million
-40,183 Reduced 15.06%
226,653 $12.3 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $523,507 - $646,811
11,879 Added 4.66%
266,836 $14.1 Million
Q3 2022

Nov 07, 2022

SELL
$42.7 - $59.99 $277,550 - $389,935
-6,500 Reduced 2.49%
254,957 $11.9 Million
Q2 2022

Aug 10, 2022

BUY
$43.0 - $65.64 $11.2 Million - $17.2 Million
261,457 New
261,457 $14.9 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $12.1B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.